Wockhardt's novel antibiotic, Zaynich, has received USFDA approval after a 12-year effort, sparking hopes for a turnaround after years of net losses. The drug, targeting multidrug-resistant bacteria, has a projected peak sales of $1.5 billion, potentially transforming the company's financial outlook. Investors have responded positively, with the stock surging on the news.